First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Title

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Authors

Keywords

-

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 32, Issue 18_suppl, Pages LBA4-LBA4

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-02-24

DOI

10.1200/jco.2014.32.18_suppl.lba4